



Article

Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge

Bisera Stepanovska ¹, Antonia I. Lange ^{2,3}, Stephanie Schwalm ⁴, Josef Pfeilschifter ⁴, Sina M. Coldewey ^{2,3,5}  and Andrea Huwiler ^{1,*} 

¹ Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland; bisera.stepanovska@pki.unibe.ch

² Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, D-07747 Jena, Germany; antonia.lange@med.uni-jena.de (A.I.L.); Sina.Coldewey@med.uni-jena.de (S.M.C.)

³ Septomics Research Center, Jena University Hospital, D-07747 Jena, Germany

⁴ Pharmazentrum Frankfurt/ZAFES, University Hospital, Goethe University Frankfurt am Main, Theodor-Stern Kai 7, D-60590 Frankfurt am Main, Germany; s.schwalm@med.uni-frankfurt.de (S.S.); Pfeilschifter@em.uni-frankfurt.de (J.P.)

⁵ Center for Sepsis Control and Care, Jena University Hospital, D-07747 Jena, Germany

* Correspondence: huwiler@pki.unibe.ch; Tel.: +41-31-632-3214

Received: 19 December 2019; Accepted: 10 February 2020; Published: 13 February 2020



Abstract: Sphingosine 1-phosphate (S1P) is a key bioactive lipid that regulates a myriad of physiological and pathophysiological processes, including endothelial barrier function, vascular tone, vascular inflammation, and angiogenesis. Various S1P receptor subtypes have been suggested to be involved in the regulation of these processes, whereas the contribution of intracellular S1P (iS1P) through intracellular targets is little explored. In this study, we used the human cerebral microvascular endothelial cell line HCMEC/D3 to stably downregulate the S1P lyase (SPL-kd) and evaluate the consequences on endothelial barrier function and on the molecular factors that regulate barrier tightness under normal and inflammatory conditions. The results show that in SPL-kd cells, transendothelial electrical resistance, as a measure of barrier integrity, was regulated in a dual manner. SPL-kd cells had a delayed barrier build up, a shorter interval of a stable barrier, and, thereafter, a continuous breakdown. Contrariwise, a protection was seen from the rapid proinflammatory cytokine-mediated barrier breakdown. On the molecular level, SPL-kd caused an increased basal protein expression of the adherens junction molecules PECAM-1, VE-cadherin, and β -catenin, increased activity of the signaling kinases protein kinase C, AMP-dependent kinase, and p38-MAPK, but reduced protein expression of the transcription factor c-Jun. However, the only factors that were significantly reduced in $\text{TNF}\alpha$ /SPL-kd compared to $\text{TNF}\alpha$ /control cells, which could explain the observed protection, were VCAM-1, IL-6, MCP-1, and c-Jun. Furthermore, lipid profiling revealed that dihydro-S1P and S1P were strongly enhanced in $\text{TNF}\alpha$ -treated SPL-kd cells. In summary, our data suggest that SPL inhibition is a valid approach to dampen an inflammatory response and augment barrier integrity during an inflammatory challenge.

Keywords: blood–brain barrier; endothelial integrity; inflammation; S1P lyase; junctional molecules; PKC

1. Introduction

The blood–brain barrier (BBB) is a unique barrier present in all mammals and is localized at the interface between the blood and the central nervous system (CNS). It is an evolutionary trait crucial for the maintenance of CNS homeostasis, by regulating the exchange of blood-borne molecules and cellular elements [1,2]. This highly specialized structural and biochemical barrier is created by endothelial cells that line the microvessels and differs significantly from non-CNS endothelial cells [3]. The BBB's properties are primarily determined by junctional complexes between the endothelial cells, which restrict the paracellular diffusion and preserve cell-cell contact [1]. BBB breakdown plays an important role in the pathogenesis of many CNS diseases, ranging from trauma to neurodevelopmental and neurodegenerative diseases, where proinflammatory substances or specific disease-associated proteins often mediate endothelial dysfunction [4,5]. Accordingly, restoring the barrier integrity is considered as a promising therapeutic approach, and several molecular pathways that regulate the BBB function and integrity have been described in this context [6]. One of the pathways that has been identified as a key determinant of BBB permeability is the sphingosine 1-phosphate (S1P) signaling cascade [7].

S1P is the central lipid molecule in the sphingolipid catabolism, which is generated by phosphorylation of sphingosine by the action of sphingosine kinase (SK)-1 and -2 [8]. The physiological importance of S1P is substantial, since it is ubiquitously distributed [9] and regulates a myriad of cellular responses, including survival, proliferation, migration, and differentiation [10]. S1P primarily acts as an extracellular high-affinity ligand and an activator of the five G protein-coupled receptors named S1P₁₋₅ [11]. Signaling downstream of the S1P receptors modulates lymphocyte trafficking, vascular tone, vascular barrier function, cardiac development, and many other critical processes [12]. Furthermore, S1P can act as an intracellular second messenger to antagonize apoptotic signals and regulate the Ca²⁺ homeostasis [13]. However, these intracellular functions are not fully understood, and direct targets are still elusive.

To preserve the intracellular sphingolipid balance, which is known as “sphingolipid rheostat”, the cells exploit a series of enzymes that reversibly backconvert S1P to sphingosine, including lipid phosphate phosphatases and S1P phosphatases, or that irreversibly degrade S1P to hexadecenal and ethanolamine-phosphate and thereby terminate signaling. The latter is catalyzed by the endoplasmic reticulum-resident enzyme S1P lyase (*Sgpl1*, SPL) [14,15].

Several S1P receptors have been suggested to be involved in the development and maintenance of endothelial barrier properties. S1P in the blood at physiological concentrations activates S1P₁ on the endothelial cells and induces barrier enhancement [7,16] by the modulation of cytoskeletal forces [17] and the redistribution of tight junction proteins [18]. S1P₅ expressed on brain endothelial cells also contributes to optimal barrier formation [19], while an opposite function was described for S1P₂, which induces stress fiber formation and prevents the proper localization of cell–cell junctions, resulting in enhanced barrier permeability [20]. S1P₃ seems to act in a similar fashion as S1P₂, as S1P₃ inhibition functionally tightens the blood–tumor barrier in brain metastases [21], whereas S1P₃ ligation, following intratracheal delivery of S1P, causes pulmonary edema via endothelial/epithelial barrier disruption [22]. Obviously, an important component of the mechanism of the action of extracellular S1P (eS1P) is the intercellular junctional complexes, which include the adherens and tight junction molecules and also several adhesion proteins outside of the specialized junctional complexes.

In contrast to the vast knowledge about the S1P receptor-mediated functions of eS1P, much less is known about the effects of the intracellular S1P (iS1P) in endothelial cells and, in particular, the impact on barrier function. In the present study, we used an SPL knockdown (kd) approach in endothelial cells derived from the BBB, HCMEC/D3, to evaluate the implications of increased intracellular S1P levels on endothelial phenotype markers, responses to inflammatory stimuli, and the consequences on barrier tightness. As the reports on SPL involvement in endothelial function are sparse and mainly derived from endothelial cells from non-CNS vascular beds, this is the first study that investigates the vasculoprotective role of SPL in the brain endothelium under inflammatory conditions.

In this study, we demonstrate that, in S1P lyase (SPL-kd) cells, transendothelial electrical resistance, as a measure of barrier integrity, was regulated in a dual manner. Unstimulated SPL-kd cells had a more destabilized barrier, whereas in an inflammatory setting, SPL-kd mediated protection from proinflammatory cytokine-mediated barrier breakdown. We show that SPL-kd resulted in a substantial accumulation of intracellular S1P and dihydro-S1P and various other molecular factors that could contribute to the protective effect. These data suggest that SPL modulation is a valid approach to dampen an inflammatory response and enhance barrier integrity during an inflammatory challenge in brain endothelial cells. Finally, they provide a clue how to treat diseases characterized by inflammation-mediated BBB disruption.

2. Results

Many studies have shown that S1P helps to maintain vascular endothelial barrier integrity which mainly occurs through S1P receptor signaling. In order to evaluate the effect of intracellular S1P on BBB function, we stably downregulated SPL in the human cerebral microvascular endothelial cell line HCMEC/D3 by transduction of cells with a lentiviral construct containing SPL-specific shRNA or an empty vector as a control. Knockdown efficiency was 99% on the SPL protein level (Figure 1A) and 95% on the mRNA level (Figure 1B). Interestingly, SPL-kd cells changed their morphology from a typical cobblestone shape to a rather spindle-shape phenotype (Figure 1C). To further characterize the SPL-kd cells, cellular S1P and dihydro-S1P were quantified by mass spectrometry. The results show an approx. 6-fold increase of iS1P in the SPL-kd cells as compared to the control cells (Figure 1D) and a small, but significant, change in the levels of dihydro-S1P (Figure 1E). When exogenous sphingosine was added to ensure sufficient substrate for SKs, endogenous S1P accumulated manifold and further increased by SPL-kd (Figure 1D).




Figure 1. Characterization of a stable SPL knockdown in HCMEC/D3 cells. HCMEC/D3 cells, transduced with either an empty lentiviral vector (ctrl) or a lentiviral vector containing SPL shRNA (SPL-kd), were cultured until confluence and were then incubated for 4 h in serum-free DMEM. Proteins and RNA were extracted and taken for either a Western Blot analysis of the SPL protein (A), or a qPCR analysis of SPL mRNA (B). (C) Subconfluent cells grown on gelatin-coated dishes were photographed using a light microscope (Zeiss AxioObserver Z1, Feldbach) with a 200× total magnification and phase contrast setting. (D,E) Control (ctrl) and SPL-kd cells were rendered serum-free for 24 h and were treated for the last 10 min with either vehicle (-) or 1 μM of sphingosine (sph). The lipids were then extracted and processed for LC-MS/MS as described in the Methods section. The results in A and B are expressed as % of the control transduced cells and are depicted as means ± S.D. ($n = 3$ in A, $n = 4$ in B, *** $p < 0.001$). Results in D and E are expressed as pg/1,5 × 10⁶ cells and are means ± S.D. ($n = 3$; * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$ considered statistically significant when compared to the vehicle-treated control; # $p < 0.05$ compared to the sphingosine-treated control; § $p < 0.05$, §§ $p < 0.01$ compared to the vehicle-treated SPL-kd).

In order to detect the differences in the endothelial barrier integrity of HCMEC/D3 control and SPL-kd cells, an electric cell-substrate impedance sensing (ECISTM) assay was used. First, an initial cell number titration was performed to determine the optimal cell number and time frame of the assay.

Control HCMEC/D3 and SPL-kd cells were seeded with a density between 20,000 and 50,000 cells/mL to determine a cell concentration resulting in a stable, long-term barrier function. All cell densities of tested control cells showed a long-term, stable barrier function after 96 h (Figure 2). In contrast, SPL-kd cells reached a short barrier plateau (12 h duration) with a subsequent barrier breakdown (Figure 2). As a stable barrier function developed at a cell density of 50,000 cells/mL in both cell types during an overlapping time interval, this density was chosen for further experiments.




Figure 2. Cell number titration of HCMEC/D3 control and SPL-kd using ECISTM. HCMEC/D3 control cells (continuous lines) and SPL-kd cells (dashed lines) were seeded at densities between 20,000 and 50,000 cells/mL. ECISTM measurements were monitored over an observation period of 216 h and were performed as described in detail in the Methods section. Partial medium changes were performed every 24 h until $t = 72$ h. The data are shown as mean curves of triplicate samples.

Proinflammatory factors, including the bacterial product lipopolysaccharide (LPS) and cytokines such as tumor necrosis factor (TNF)- α , interleukin (IL)-1 β , IL-6, and interferon (IFN)- γ , are known to affect the stability of endothelial barriers. To elucidate the impact of inflammatory stimuli on HCMEC/D3 control and SPL-kd cells, we performed a dose-response experiment (1:100, 1:400, 1:800 and 1:1000) using ECISTM (Figure 3). After 24 h, we observed a significant decrease of resistance only in control cells induced by a dilution of 1:100 of LPS plus cytokine mix (LPS + Cyt), indicating an initial barrier breakdown, whereas both cell types showed no decline of resistance at LPS + Cyt dilutions of 1:400, 1:800, and 1:1000. At 120 h after administration of the inflammatory stimulus, we observed an on-going barrier breakdown in HCMEC/D3 cells by LPS + Cyt 1:100. However, also, the higher LPS + Cyt dilutions caused significantly extenuated barrier stability in HCMEC/D3 cells. As seen before, SPL-kd without LPS + Cyt could not maintain barrier stability on a long-term basis; only when applying inflammatory stimuli, SPL-kd significantly strengthened the endothelial barrier (Figure 3).

We further investigated whether SPL-kd cells are differentially equipped with junctional molecules, which could explain the observed phenotype in barrier integrity. The expression of various adherens junction molecules under resting and inflammatory conditions was evaluated. As seen in Figure 4 and Figure S1, SPL-kd cells showed an increased basal protein expression level of the platelet and endothelial cell adhesion molecule (PECAM-1) compared to the control cells, which is reduced upon stimulation with the proinflammatory cytokine TNF α but still remained at a much higher level in SPL-kd cells than in the control cells. Vascular endothelial cadherin (VE-cadherin) and β -catenin were also increased by SPL-kd but were not altered by TNF α stimulation. The levels of p120 catenin and the adaptor protein zonula occludens-1 (ZO-1) were not affected by SPL-kd or TNF α . The increased protein expression of PECAM-1 and VE-cadherin was in line with the increased mRNA expression by the SPL-kd (Figure S2A,B), whereas β -catenin mRNA (Figure S2C) was not significantly changed by SPL-kd or by TNF α . However, since one of the downstream targets of β -catenin, Axin2 [23], was upregulated by SPL-kd and reduced by TNF α on mRNA level (Figure S2D), we conclude that the regulation of β -catenin by SPL-kd occurs on the post-translational level and has downstream consequences.




Figure 3. Impact of an inflammatory stimulus (lipopolysaccharide (LPS) + Cyt) on the barrier integrity of HCMEC/D3 control and SPL-kd cells. After the development of a stable barrier ($t = 0$ h), HCMEC/D3 control cells (continuous line) and SPL-kd cells (dashed line) were stimulated with different dilutions of an inflammatory stimulus (LPS + Cyt). Resistance values were analyzed at the two observation time points 24 h and 120 h (indicated by dotted arrows) after LPS + Cyt administration. The data are expressed as a mean \pm S.D. ($n = 3$), * $p < 0.05$.




Figure 4. Effect of SPL knockdown on the expression of adherens junction molecules in TNF α -stimulated HCMECs. Confluent control (ctrl) and SPL-kd HCMEC/D3 cells were incubated for 4 h in serum-free DMEM before stimulation for 24 h with either vehicle (-) or 1 nM TNF α in DMEM/0.1% FBS. The proteins were extracted, separated by SDS-PAGE, transferred to nitrocellulose membrane and subjected to analysis using antibodies against PECAM-1, VE-cadherin, β -catenin, p120, ZO-1 and α -tubulin. Data show representative blots, out of 3 independent experiments, performed in triplicates. The evaluation of the respective bands is presented in Figure S1.

Furthermore, in endothelial cells, TNF α markedly induces the synthesis of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), which are both known to facilitate leukocyte transmigration [24]. Here, TNF α stimulation resulted in a strong induction of ICAM-1 (Figure 5A, Figure S3A) and VCAM-1 protein (Figure 5A, Figure S3B) as well as of their mRNA expressions (Figure 5B,C). We found that in SPL-kd cells, only VCAM-1 expression, but not ICAM-1, was significantly reduced by SPL-kd, suggesting a potential attenuation of leukocyte recruitment in SPL-kd. Moreover, gene expression of inflammatory products including monocyte chemoattractant protein 1 (MCP-1/CCL2), IL-6 and IL-8, were all induced by TNF α treatment, but only MCP-1 and IL-8

were significantly downregulated in SPL-kd cells (Figure 6A–C), whereas IL-8 expression was rather enhanced by SPL-kd (Figure 6D).




Figure 5. Effect of TNF α stimulation on the protein and mRNA expression of adhesion molecules in control and SPL-kd HCMEC/D3. Confluent control (ctrl) and SPL-kd HCMEC/D3 cells were rendered serum-free for 4 h prior to stimulation for 24 h with either vehicle (–) or 1 nM TNF α in DMEM/0.1% FBS. Thereafter, cells were taken for either protein extraction and Western Blot analysis of ICAM-1, VCAM-1, and α -tubulin (A), or RNA extraction and qPCR analysis of ICAM-1 and VCAM-1 (B,C). The results are expressed as % of control transduced cells and are means \pm S.D. The evaluation of the respective bands (A) is presented in Figure S3. ($n = 3$ for A, $n = 4$ –6 for B–C; **** $p < 0.0001$ compared to the vehicle-treated control; # $p < 0.05$ compared to the TNF α -treated control; § $p < 0.05$, §§§§ $p < 0.0001$ compared to the vehicle-treated SPL-kd).

To further delineate the mechanism of the SPL-kd-mediated protection of barrier integrity under inflammatory conditions, we investigated various key signaling cascades and transcription factors. VCAM-1, MCP-1, IL-6, and IL-8 are all known to be critically regulated by the transcription factor nuclear factor κ B (NF κ B). In view of a previous report showing that intracellular S1P can directly bind to the TNF receptor-associated factor 2 (TRAF2) and trigger NF κ B activation [25], we here determined whether NF κ B was affected by SPL-kd. Phosphorylation of the p65 subunit of NF κ B occurs upon TNF α stimulation and precedes the nuclear translocation and transcriptional regulation of target genes [26]. In SPL-kd cells, we did not observe any difference in TNF α -stimulated p65-NF κ B phosphorylation compared to the control cells (Figure S4), thus excluding a link between iS1P and NF κ B activation in this HCMEC system.

Two protein kinases that showed enhanced phosphorylation and activity by SPL-kd were p38-MAPK and the AMP-activated protein kinase (AMPK) (Figure 7A). Additionally, the total protein expression level of the transcription factor c-Jun, as well as its phosphorylation at Ser⁶³ were reduced in SPL-kd, whereas JunB was not altered (Figure 7A). No significant changes in phospho-p42/p44-MAPK, phospho-Akt, and phospho-SAPK/JNK were observed by SPL-kd (Figure S5). Other transcription factors, including KLF2 and KLF4, which are considered as “molecular switches” regulating important aspects of vascular function and leukocyte adhesion [27,28], were found to be enhanced on the mRNA level but unchanged on the protein level (Supplementary Figure S6). Interestingly, the protein kinase C (PKC) family was also found to be activated by SPL-kd. Since PKC consists of at least 11 isoenzymes, and so far single isoenzyme’s activities cannot be measured in cellular systems, we analyzed the total cellular PKC activity by determining the phosphorylation pattern of PKC substrates using a phospho-specific PKC substrate and a phospho-MARCKS antibody (Figure 7B). Notably, two bands of approx. 30 kDa and 40 kDa were clearly upregulated by SPL-kd and a similar pattern was observed for the major PKC substrate, MARCKS. These bands were also upregulated by short-term phorbol ester (TPA) stimulation.




Figure 6. Effect of TNF α treatment on MCP-1, IL-6, and IL-8 expression in control and SPL-kd HCMEC/D3. A human MCP-1 ELISA kit was used to quantify secreted MCP-1 from vehicle and TNF α -stimulated HCMEC/D3 (A). (B–D): cells stimulated for 24 h with either vehicle (–) or 1 nM TNF α in DMEM/0.1% FBS were taken for RNA extraction and qPCR analysis using primers for MCP-1 (B), IL-6 (C), and IL-8 (D). Results in A are expressed as ng/mL MCP-1 in the supernatant and are means \pm S.D. ($n = 3$). The results in B–D are expressed as % of vehicle-treated control cells and are means \pm S.D. ($n = 3$); ** $p < 0.01$, **** $p < 0.0001$ compared to the vehicle-treated control; ### $p < 0.001$, #### $p < 0.0001$ compared to the TNF α -treated control; §§ $p < 0.01$, §§§§ $p < 0.0001$ compared to the vehicle-treated SPL-kd.




Figure 7. Effect of SPL-kd on various signaling molecules and transcription factors. Confluent control (ctrl) or SPL-kd HCMEC/D3 cells were rendered serum-free for 4 h prior to stimulation with either vehicle (–), 1 nM TNF α (A) or 50 nM TPA (B) in serum-free DMEM for 10 min. Protein extracts were separated by SDS-PAGE and subjected to Western blot analysis using antibodies against phospho-p38-MAPK, total p38-MAPK, phospho-AMPK α , total AMPK α , phospho-c-Jun, total c-Jun, JunB, phospho-protein kinase C (PKC) substrates, phospho-MARCKS, and α -tubulin. The data show representative blots, out of 3–4 independent experiments, performed in triplicates.

A previous study reported that iS1P can directly inhibit histone deacetylases (HDACs) [29] and that, by such epigenetic interference, iS1P may regulate the expression of various genes. We therefore tested here whether SPL-kd affects overall cellular HDAC activity by using an in situ fluorometric assay and by detecting histone H3 lysine 3 acetylation, as the most reported residue connected to iS1P, by Western Blot analysis. However, in SPL-kd cells, no change in either overall cellular HDAC activity (Figure S7A) or in acetylated histone H3 (Figure S7B) as a target of HDAC1/2 occurred.

To further investigate whether certain sphingolipid species are differentially affected by TNF α treatment in SPL-kd cells, lipid extracts of cells were quantified by mass spectrometry. S1P levels, which were markedly enhanced in SPL-kd cells, were only slightly increased by TNF α treatment in control cells but showed a synergistic increase in TNF α plus SPL-kd (Figure 8A). Dihydro-S1P showed a similar regulation and was also synergistically increased by TNF α plus SPL-kd (Figure 8B). The precursor of these lipids, sphingosine, was also increased, whereas sphinganine and many ceramides and glycosylated ceramides were rather downregulated (Table S1). This lipid pattern suggests a negative feedback in the de novo pathway with a potential impact on SK-1 expression, which is downregulated on both the protein and mRNA level (Figure S8), possibly as a mechanism to divert sphingosine from further S1P production.




Figure 8. Effect of TNF α on S1P (A) and dihydro-S1P (B) content in HCMEC/D3 cells. Confluent control (ctrl) and SPL-kd cells were rendered serum-free for 24 h prior to stimulation for 24 h with either vehicle (-) or 1 nM TNF α . Lipids were extracted and quantified by LC-MS/MS. The results are depicted as picograms per 1.5×10^6 cells and are means \pm S.D. ($n = 3$; * $p < 0.01$, ** $p < 0.001$, **** $p < 0.0001$ considered statistically significant when compared to the vehicle-treated control; ##### $p < 0.0001$ compared to the TNF α -treated control; §§§§ $p < 0.01$ compared to the vehicle-treated SPL-kd).

Finally, to study the role of extracellular S1P on the barrier integrity of HCMEC/D3 control and SPL-kd cells, we performed a pre- and post-treatment with S1P (10 nM and 100 nM) using the ECISTM system to examine the ability of S1P to ameliorate barrier dysfunction induced by an inflammatory stimulus. Pre-treatment with S1P, given 4 h prior to LPS + Cyt stimulation, did not affect barrier stability in either cell types over the whole time period (Figures S9 and S10). Conversely, post-treatment with S1P, given 24 h after LPS + Cyt stimulation, significantly attenuated LPS + Cyt-induced barrier destabilization in control HCMEC/D3 cells, but this was only seen after 120 h (Figures S11 and S12). No effect of post-treatment with S1P was seen in SPL-kd cells (Figures S11 and S12) or with S1P alone in both cell lines (Figures S9–S12).

3. Discussion

In the present study, we demonstrate that the genetic knockdown of SPL in the human cerebral microvascular endothelial cell line HCMEC/D3 alters barrier function, which occurs in a dual manner. Under inflammatory conditions, which normally trigger a continuous and long-lasting barrier breakdown (Figure 3), SPL-kd demonstrated consolidated barrier function. However, under unstimulated conditions of endothelial junctional assembly, SPL-kd cells had a delayed barrier build up,

a shorter stable barrier plateau and thereafter a continuous breakdown (Figure 2). Obviously, SPL-kd, which primarily leads to enhanced iS1P levels, can have both barrier-protective and barrier-disruptive effects, depending on the milieu.

Increased endothelial permeability is considered a serious complication in many inflammatory diseases or as a factor that contributes to the pathology of neurodegenerative diseases, trauma, tumors, and ischemia. Such endothelial dysfunction may be induced by various factors, for instance, inflammatory cytokines, histamine, thrombin, LPS, vascular endothelial growth factor, and bradykinin [30–32]. Although these permeability-inducing factors bind to different receptors, their signaling converges mainly on the level of the adherens junction molecules VE-cadherin, β -catenin, and PECAM-1, which become disrupted due to downregulated expression or enforced internalization through phosphorylation, resulting in a diminished interaction with other junctional molecules and the actin cytoskeleton, reduced enrichment on cell-cell borders, and an overall decrease in the adhesion strength [30,31,33,34].

The protective effect of S1P on the endothelial barrier is well reported and has been confirmed *in vitro* in cell cultures of endothelial cells but also *in vivo* in the vasculature [35,36]. Upon S1P stimulation, there is a rapid strengthening of the barrier that involves various mechanisms, including Rac1 activation, phosphorylation of actin-binding proteins of the ezrin/radixin/moesin family, and the rearrangement of cytoskeletal proteins to the cell periphery [35,37]. Additionally, S1P can increase the expressions of VE-cadherin and PECAM-1 in human endothelial cells and decrease the phosphorylation-induced VE-cadherin/catenin complex destabilization [38–40]. These effects of eS1P are mediated by S1P receptors, of which most evidence is presented for S1P₁ [38,41,42], but other receptor subtypes, such as S1P₃ [43] and S1P₅ [19], may also mediate protection. In opposition to this, a rather barrier disruptive function of S1P through S1P₂ [20] and S1P₃ [21,44] has also been described.

Our data now demonstrate that iS1P is also an important for the barrier function and affects the BBB, as seen *in vitro* in endothelial cells originating from BBB. SPL-kd, which results in increased iS1P (Figure 1D), has immediate consequences on the protein expression of various adherens junctions, signaling molecules, and transcription factors, which may promote barrier protection under inflammation. These include an increased expression of VE-cadherin, PECAM-1 and β -catenin (Figure 4), and an increased activation state of PKC, AMPK, and p38-MAPK but a reduced expression of the transcription factor c-Jun (Figure 7). Upon TNF α treatment, SPL-kd cells demonstrated a strong downregulation of the adhesion molecule VCAM-1 (Figure 5) and the cytokines IL-6 and MCP-1 (Figure 6), all of which could contribute to the protective effect under inflammatory conditions. In this view, it is known that VCAM-1 is upregulated by pro-inflammatory cytokines, and upon VCAM-1 cross-linking, which mimics clustering with integrins on leukocytes, signaling is induced that increases stress fiber formation and barrier opening [45,46]. IL-6 promotes a sustained loss of endothelial barrier function via JNK-mediated STAT3 phosphorylation and *de novo* synthesis [47], while MCP-1 (CCL2) acts in an autocrine manner on the endothelial CCR2 receptor to disrupt tight and adherens junctions [48,49]. Whether the increased IL-8 synthesis in SPL-kd cells has any clinical relevance is presently unclear, but remarkably, a previous study [50] also showed that a similar effect occurred in placentas of preeclampsia patients, which expressed less SPL and had higher IL-8 levels in the circulation [50].

Although these factors are classically regulated by NF κ B, we could not see any change in NF κ B activity in the SPL-kd (Figure S4), and therefore the mechanism of downregulation by SPL-kd remains unclear. Krüppel-like factors (KLF) are reported to inhibit the transcriptional activity of NF- κ B by competing for its transcriptional coactivators and thereby down-regulating its expression of proinflammatory genes [51]. For instance, KLF2 is known as a key transcriptional regulator of endothelial proinflammatory activation, by the inhibition of the cytokine-mediated induction of VCAM-1 expression, without affecting the expression of ICAM-1 and, similarly, the depletion of KLF4 acted proinflammatory by the enhancement of TNF α -induced VCAM-1 expression [52,53]. Although we detected significantly higher mRNA levels of KLF2 and KLF4, their protein levels

remained equal between control and SPL-kd cells (Figure S6). Therefore, the contribution of KLF2 and KLF4 for the observed anti-inflammatory response in the SPL-kd cells can be excluded. We also identified the transcription factor c-Jun to be significantly reduced in SPL-kd (Figure 7A). We therefore speculate that this reduction of c-Jun at least partially contributes to the observed barrier protection. This is in agreement with a previous study that specifically targeted c-Jun expression, which resulted in the suppression of vascular permeability and inflammation [54]. It is also likely that the diminished expression of c-Jun accounts for the lower expression of VCAM-1, as it was shown that the AP-1 complex mediates the effect of TNF- α in the regulation of VCAM-1 expression through the modulation of the NF- κ B transactivation in endothelial cells [55]. In addition, p38-MAPK may independently or synergistically regulate the effects of TNF α , and it was demonstrated that the inhibition of this kinase suppressed the TNF α -induced expression of VCAM-1 without affecting ICAM-1 and that this stress kinase cascade is critical for the TNF α -induced expression of MCP-1 in endothelial cells [56,57]. This clearly opposes our findings, as we found a constitutive increase in p38-MAPK with a decreased basal production of MCP-1 and TNF α -induced VCAM-1, which corroborates the controversial role of the p38 pathway [58].

The barrier-protective effect of iS1P is in agreement with a previous study by Li et al. [59], who showed that mice transgenic for SK-1 in endothelial cells have a reduced vascular leakiness upon angiopoietin-1 treatment, and that this protective effect is independent of eS1P and S1P receptors. This was further confirmed by Zhao et al. [60] in another approach of targeting the degrading enzyme SPL. They showed that in human lung microvascular endothelial cells, or in heterozygous SPL (+/-) mice, the loss of SPL reduced LPS-triggered barrier breakdown and pulmonary permeability. The authors also suggested that the protection from lung endothelial barrier disruption is mediated by accumulated iS1P and requires coupling to S1P₁ and subsequent Rac1 activation. Obviously, there is an inconsistency whether iS1P acts dependent on S1P receptors or not. Moreover, a study using intravital microscopy in a murine atherosclerosis model revealed that iS1P reduced leukocyte adhesion to capillary wall and decreased LPS-induced endothelial permeability [61], thus corroborating our findings.

In opposition to the restorative effect of SPL-kd in an inflammatory setting, our data show a barrier-disruptive effect of SPL-kd in the early phase of barrier build up. Biphasic barrier regulation has also been reported by other stimuli. In this regard, an androgen-like steroid, LPS, and cyclic nucleotides, demonstrated a dual manner of barrier regulation, which is concentration dependent and involves changes in the actin cytoskeleton, protein kinase A, and PI3K/Akt pathways among others [62–65]. Although SPL-kd cells possess enhanced expression of several factors important for barrier consolidation, these factors are not, per se, sufficient to support the barrier function in the initial phase of junctional assembly, and the mechanism of this is still unclear.

Various mechanisms can contribute to the basal assembly of endothelial junctions and among these are calcium and multiple protein kinases, including PKC, AMPK, protein kinase A, myosin light-chain kinase, non-receptor tyrosine kinases, and Rho-dependent kinase [66–68]. For instance, PKC and intracellular Ca²⁺ [69] were reported to promote junction assembly in MDCK cells, whereas already assembled junctions are destabilized by factors such as thrombin through PKC activation and increased intracellular Ca²⁺ [70]. Since SPL knockout in mouse embryonic fibroblasts (MEF) has been shown to enhance intracellular calcium levels [71,72], and since the inhibition of S1P synthesis by sphingosine kinase inhibition decreases Ca²⁺ mobilization and permeability in human umbilical vein endothelial cells [73], it is well conceivable that also in HCMECs, the downregulation of SPL causes changes in intracellular Ca²⁺ levels, which could regulate junctional assembly and disassembly. As conventional PKCs are usually activated by Ca²⁺, we studied the pattern of PKC substrates' phosphorylation and MARCKS phosphorylation and could indeed see changes in PKC activity (Figure 7B). Notably, the phosphorylations of 30 kDa and 40 kDa substrates were increased in SPL-kd, suggesting that iS1P may either directly or indirectly activate PKC. This dual effect of PKC can be explained by the fact that PKC is not just one entity, but rather a family consisting of 11 different isoforms, which can

exert diverse and even opposite functions. In this regard, PKC- α , PKC- β , - θ , and - ζ activities were attributed to increased endothelial permeability [74–77], whereas PKC- δ and PKC- ϵ can mediate barrier protection [78,79]. It is also worth noting that in the livers of SPL-deficient mice [80] and in MEFs isolated from SPL-deficient mice [81], diacylglycerols, which are well known direct PKC activators, were reported to be significantly increased, thus further supporting the conclusion that SPL-kd couples to enhanced PKC activity.

To examine the efficacy of S1P to ameliorate the barrier dysfunction induced by an inflammatory stimulus, we performed a pre- and post-treatment with S1P. Our data show that in control HCMEC/D3 cells, eS1P by itself, or eS1P added as a stimulus prior to an inflammatory mixture, could not strengthen the endothelial barrier. Only in an inflammatory setting, post-treatment with eS1P had a protective effect on the cytokine-induced barrier breakdown (Figures S11 and S12). Notably, this protective effect was seen at a late time point (120 h), but not at early time points (48 h). It may be speculated that this phenomenon is mediated by gene transcriptional mechanisms and *de novo* protein synthesis, which are triggered by eS1P and require a prolonged period until detection. The protective effect of post-treatment eS1P in the inflammatory setting was abolished in the SPL-kd cells (Figures S11 and S12), suggesting that either the expression of S1P receptors are altered by the knockdown and thus the responsiveness towards eS1P or that the barrier improving effect by SPL-kd is already maximal and cannot be further enhanced by additional eS1P. In this context, it is of interest that the barrier improving effect of eS1P cannot be seen in all types of endothelial cells. In a comparative study between dermal microvascular endothelial cells (HMEC-1) and glomerular endothelial cells (GENC), it was shown that eS1P could only improve the barrier function in HMEC-1, but not in GENC [82]. The protective effect was dependent on the ability of eS1P to stimulate AMPK, which was seen in HMEC-1 but not in GENC.

To see whether the protective effect of SPL-kd under inflammatory conditions correlates with a change in certain sphingolipid subspecies, a more extended analysis of sphingolipids was performed by LC-MS/MS (Figure 8 and Table S1). Previous studies demonstrated that not only S1P, but also other sphingolipid molecules, such as sphingomyelin [83], ceramides, and very long-chain ceramides [84,85], are involved in endothelial barrier regulation. In agreement with this, other sphingolipid species may mediate the response towards inflammatory stimuli, as we have seen from the LC-MS/MS data that S1P and dihydro-S1P, which are both modestly increased by TNF α in control cells, synergistically increase by TNF α in SPL-kd (Figure 8). Ceramides of various chain lengths were decreased in HCMEC/D3 SPL-kd (Table S1), which is in accordance to a previous study in SPL-deficient HeLa cells [81]. According to Linder et al. [84], ceramides have the potential to alter endothelial cell permeability. Nevertheless, S1P and dihydro-S1P remain the only measured sphingolipids showing a unique pattern of increase in SPL-kd cells under inflammatory conditions. Since several studies have indicated a positive correlation between reduced dihydro-S1P and reduced endothelial barrier function [86], further investigation is required to elucidate to what extent dihydro-S1P is involved in the biphasic resistance response of SPL-kd.

Although most of the BBB characteristics are determined by endothelial cells, they coexist with pericytes and astrocytes and the surrounding extracellular matrix which maintain their characteristics [87]. Since our data were generated in immortalized brain endothelial cells, this bears the risk of undermining the barrier attributes that emanate from the continuous crosstalk of endothelial cells with mural and glial cells. Thus, it would be important to validate our findings in a co-culture system and expand our analysis on the tight junctions, which are crucial for BBB integrity.

Altogether, our data suggest that SPL inhibition is a valid approach to dampen an inflammatory response and increase barrier integrity during an inflammatory challenge in brain endothelium and it provides a clue how to treat diseases characterized by inflammation-mediated BBB disruption.

4. Materials and Methods

4.1. Chemicals

All chemicals, primer sequences, and commercial and in-house produced antibodies, are indicated in the supplementary data file.

4.2. Cell Culturing and Stable SPL Knockdown Generation

Immortalized human cerebral microvascular endothelial cell line (HCMEC/D3) was purchased from CELLutions Biosystems Inc., Ontario, Canada (Catalogue Number: CLU512) and was maintained according to manufacturer's instructions, with the variation of using DMEM as basal medium supplemented with 5% FBS from PAN-Biotech, 1.4 μ M hydrocortisone, 5 μ g/mL ascorbic acid, 5 mL CD lipid concentrate, 10 mM HEPES, and 1 ng/mL bFGF. Cells were passed 2–3 times a week, using Trypsin-EDTA 0.25% for dissociation, and were used within passages 27–40. Flasks were pre-coated with autoclaved 1% gelatin in phosphate-buffered saline (PBS) and incubated for 1 h in incubator to allow polymerization.

The stable knockdown of SPL in HCMECs was achieved by transduction with lentiviral short hairpin RNA (shRNA) construct from Sigma MISSION[®] following the respective protocols. Two different constructs were tested in parallel (TRCN0000286832 and TRCN0000078314), and the clone that yielded strongest gene silencing (TRCN0000286832) was used further. Cells were further named SPL-kd. Virus control cells were generated with TRC2 pLKO.5-puro empty vector control plasmid DNA from the same company. For the selection of resistant colonies, 1.5 μ g/mL of puromycin was added to the medium in accordance with the results from previous titration. Knockdown efficiency was confirmed by quantitative PCR, Western Blot analysis, and by an LC-MS/MS to determine intracellular S1P accumulation.

All cells were cultured in the environment of 37 °C in an atmosphere enriched with 5% CO₂. Prior to stimulation, they were rendered serum-free for 4 h or 24 h with a medium consisting of DMEM, 0.1 mg/mL BSA, and 10 mM HEPES (later on referred as DMEM serum-free), unless otherwise stated.

4.3. Western Blot Analysis

Stimulated cells were washed with ice-cold PBS and were subsequently scraped with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X100, 2 mM EDTA pH 8.4, 2 mM EGTA pH 8.0, 40 mM β -glycerol phosphate, 50 mM NaF, 10 mM sodium pyrophosphate, 2 mM DTT, 200 μ M Na₃VO₄, 400 μ L reconstituted cComplete[™] protease inhibitor cocktail, and 10 μ M PMSF). Cells were homogenized by sonication (5 s at 30 microns peak to peak amplitude; *n*. Zivy & Co Ltd., Oberwil, Switzerland), lysates were centrifuged for 10 min at 13,000 rpm, and the supernatant was taken for protein determination according to Bradford. The samples were dissolved in Laemmli buffer separated by SDS-PAGE followed by protein transfer to nitrocellulose membrane by wet blotting using a buffer containing 25 mM Tris, 190 mM glycine and 20% (v/v) methanol. Membranes were blocked with 3% (w/v) low-fat milk powder in PBS for 1 h and were then incubated with the respective antibodies and diluted in a buffer containing 50 mM Tris-HCl pH 7.4, 200 mM NaCl, 10% (v/v) horse serum, 3% (w/v) BSA fraction V, and 0.1% (v/v) Tween20.

4.4. RNA Extraction and Quantitative PCR Analysis

Stimulated cells were washed with ice-cold PBS and homogenized in RNA-Solv[®] reagent. Total RNA extraction was performed according to the instructions of the manufacturer. The yield and purity of the isolates were assessed with a NanoDrop[®] ND-1000 spectrophotometer (Witec AG, Littau, Switzerland), and first strand cDNA was synthesized using 1 μ g total RNA as template. SYBR[®] Green-based quantitative PCR was performed in a BioRad CFX Connect[™] Optics Module thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA, USA). The Bio-Rad CFX Manager software was used to

monitor the melting curve, and to obtain the quantification data. The relative mRNA expression of the gene of interest was calculated with the $\Delta\Delta C_t$ method normalized to 18S RNA as a housekeeping gene.

4.5. MCP-1 ELISA

A human MCP-1 PicoKine™ ELISA kit (Boster Biological Technology, Pleasanton, CA, USA) was used to quantify MCP-1 in cell culture supernatants according to the manufacturer's instructions. Confluent cells in 100 mm-diameter dishes were incubated for 4 h in DMEM serum-free prior to stimulation with 1 nM TNF α . Cell supernatants were collected, centrifuged for 5 min at 14,000 $\times g$ and 4 °C, and the supernatant was used in a 1:100 dilution.

4.6. Quantification of Sphingolipids by LC-MS/MS

Cell monolayers in 60 mm-diameter dishes were trypsinized, pelleted, and resuspended in methanol containing C17-sphingolipids as internal standards and were subjected to lipid extraction and LC-MS/MS analysis, as previously described [88].

4.7. Barrier Integrity Measurements Using the ECIS™ System and Inflammatory Stimulus Preparation

The endothelial barrier integrity of the confluent HCMEC/D3 control and SPL-kd monolayers was assessed using an electric cell-substrate impedance sensing (ECIS™) Z θ system (Applied Biophysics Inc., Troy, NY, USA). ECIS is a real-time and impedance-based method to study the barrier dynamics of cells grown onto gold-film wells. Semi-confluent HCMEC/D3 control and SPL-kd cells (passage 44–46) were seeded on 96W10idf ECIS Cultureware™ Arrays (Applied Biophysics Inc., Troy, NY, USA), which were pre-coated with human fibronectin (1 mg/mL) and murine collagen IV (1.25 mg/mL) in Hank's balanced salt solution for 30–60 min. Partial media changes were performed every 24 h until a steady state of resistance (approx. 1100–1400 Ω) was reached, corresponding with the development of a confluent monolayer by the time stimulation experiments were commenced. ECIS experiments were continuously monitored for 5–6 days to capture both acute and longer-term changes in the endothelial resistance. The impedance of cell-covered electrodes was measured with the multiple frequencies over time (MFT) mode to record the impedance measurements over a broad spectrum of frequencies. The resistance represents the integrity of cell barriers and was monitored at 4000 Hz. Each measurement was performed in triplicates. The time was resampled to 600 s and the medium control was subtracted from the mean value of each measurement. In the barrier integrity experiments, an inflammatory stimulus was used. The stock solution of the inflammatory stimulus (LPS + Cyt) consisted of lipopolysaccharide (LPS, 10 $\mu\text{g/mL}$, *E. coli* O111:B4) and the pro-inflammatory cytokines TNF- α (5 $\mu\text{g/mL}$), IL-1 β (1 $\mu\text{g/mL}$), IFN- γ (1 $\mu\text{g/mL}$), and IL-6 (1 $\mu\text{g/mL}$) in DMEM/1% (w/v) BSA. The cells were incubated with either 1:100, 1:400, 1:800, or 1:1000 LPS + Cyt dilutions. S1P was solubilized in methanol and applied to cells in a final concentration of 10 nM or 100 nM as pre- (4 h before LPS + Cyt) or post-treatment (24 h after LPS + Cyt).

4.8. Statistical Analysis

Statistical analysis was performed by one-way ANOVA or an unpaired *t*-test where applicable. For multiple comparisons, the level of significance was calculated with Bonferroni correction. GraphPad Prism Software, version 6, (San Diego, CA, USA) was used for statistical analysis and graph presentations. For ECIS™ resistance curves, mean values and standard deviations were plotted against time starting after LPS + Cyt or S1P stimulation. The statistics were verified as two-way ANOVA with $\alpha = 0.05$ and Bonferroni's multiple comparisons test. The data are depicted as means \pm S.D. for *n* number of replicates and are representatives from 3 independent experiments.

Supplementary Materials: Supplementary materials can be found at <http://www.mdpi.com/1422-0067/21/4/1240/s1>.

Author Contributions: B.S., A.I.L., J.P., S.M.C. and A.H. conceived and designed the experiments; B.S., A.I.L. and S.S. performed the experiments; B.S., A.I.L., S.M.C. and A.H. analyzed the data; B.S., S.M.C. and A.H. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Swiss National Foundation (310030_175561/1, to A.H.), the Swiss Society for Multiple Sclerosis (to A.H.), the Deutsche Forschungsgemeinschaft (SFB1039 to J.P.), the Federal Ministry of Education and Research (BMBF) (ZIK Septomics Research Centre, Translational Septomics, award no. 03Z22JN12 to S.M.C.). We thank Dr. D. Thomas (Institute of Clinical Pharmacology, University Hospital Frankfurt) for the LC-MS/MS analysis, Prof. Britta Engelhardt and Prof. Uwe Zangemeister-Wittke for helpful discussions, and Mrs Tankica Maneva-Timcheva, Marianne Maillard-van Laer and Isolde Römer for excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

AMPK α	adenosine monophosphate-activated protein kinase alpha
ANOVA	analysis of variance
BBB	blood-brain barrier
BSA	bovine serum albumin
cDNA	complementary deoxyribonucleic acid
CNS	central nervous system
Ctrl	control
DMEM	Dulbecco's modified Eagle medium
ECIS	electric cell-substrate impedance sensing
ELISA	enzyme-linked immunosorbent assay
eS1P	extracellular sphingosine 1-phosphate
FBS	fetal bovine serum
HCMEC/D3	human cerebral microvascular endothelial cells clone D3
HDAC	histone deacetylase
ICAM-1	intercellular adhesion molecule 1
IL	interleukin
INF- γ	interferon gamma
iS1P	intracellular sphingosine 1-phosphate
kd	knockdown
KLF	Krueppel-like factor
LC-MS/MS	liquid chromatography–mass spectrometry
LPS	lipopolysaccharide
LPS + Cyt	LPS + cytokine mix
MAPK	mitogen-activated protein kinase
MARCKS	myristoylated alanine-rich C-kinase substrate
MCP-1	monocyte chemoattractant protein 1
mRNA	messenger ribonucleic acid
NF κ B	nuclear factor kappa-light-chain-enhancer of activated B cells
PBS	phosphate-buffered saline
PECAM-1	platelet and endothelial cell adhesion molecule 1
PKC	protein kinase C
qPCR	quantitative polymerase chain reaction
SAPK/JNK	stress-activated protein kinase/c-Jun-N-terminal kinase
SD	standard deviation
SDS-PAGE	sodium dodecyl sulfate- polyacrylamide gel electrophoresis
shRNA	short hairpin ribonucleic acid
SK	sphingosine kinase
SPL/Sgpl1	sphingosine 1-phosphate lyase
TNF α	tumor necrosis factor alpha
TPA	12-O-tetradecanoylphorbol-13-acetate

TRAF2	TNF receptor-associated factor 2
VCAM-1	vascular cell adhesion molecule 1
VE-cadherin	vascular endothelial cadherin
ZO-1	zonula occludens 1

References

1. Stamatovic, S.M.; Keep, R.F.; Andjelkovic, A.V. Brain endothelial cell-cell junctions: How to “open” the blood brain barrier. *Curr. Neuropharmacol.* **2008**, *6*, 179–192. [[CrossRef](#)] [[PubMed](#)]
2. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. *Neurobiol. Dis.* **2010**, *37*, 13–25. [[CrossRef](#)] [[PubMed](#)]
3. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P.O. The blood-brain barrier in brain homeostasis and neurological diseases. *Biochim. Biophys. Acta* **2009**, *1788*, 842–857. [[CrossRef](#)] [[PubMed](#)]
4. Persidsky, Y.; Ramirez, S.H.; Haorah, J.; Kanmogne, G.D. Blood-brain barrier: Structural components and function under physiologic and pathologic conditions. *J. Neuroimmune Pharmacol.* **2006**, *1*, 223–236. [[CrossRef](#)] [[PubMed](#)]
5. Saunders, N.R.; Ek, C.J.; Habgood, M.D.; Dziegielewska, K.M. Barriers in the brain: A renaissance? *Trends Neurosci.* **2008**, *31*, 279–286. [[CrossRef](#)]
6. Ronaldson, P.T.; Davis, T.P. Blood-brain barrier integrity and glial support: Mechanisms that can be targeted for novel therapeutic approaches in stroke. *Curr. Pharm. Des.* **2012**, *18*, 3624–3644. [[CrossRef](#)]
7. Prager, B.; Spampinato, S.F.; Ransohoff, M.R. Sphingosine 1-phosphate signaling at the blood-brain barrier. *Trends Mol. Med.* **2015**, *21*, 354–363. [[CrossRef](#)] [[PubMed](#)]
8. Huwiler, A.; Pfeilschifter, J. New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets. *Biochem. Pharmacol.* **2008**, *75*, 1893–1900. [[CrossRef](#)]
9. Alemany, R.; van Koppen, C.J.; Danneberg, K.; Ter Braak, M.; Meyer zu Heringdorf, D. Regulation and functional roles of sphingosine kinases. *Naunyn Schmiedebergs Arch. Pharmacol.* **2007**, *374*, 413–428. [[CrossRef](#)]
10. Huwiler, A.; Pfeilschifter, J. Sphingolipid signaling in renal fibrosis. *Matrix Biol.* **2018**, *66–69*, 230–247. [[CrossRef](#)]
11. Blaho, V.A.; Hla, T. An update on the biology of sphingosine 1-phosphate receptors. *J. Lipid. Res.* **2014**, *55*, 1596–1608. [[CrossRef](#)] [[PubMed](#)]
12. Stepanovska, B.; Huwiler, A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. *Pharmacol. Res.* **2019**. [[CrossRef](#)] [[PubMed](#)]
13. Maceyka, M.; Harikumar, K.B.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. *Trends Cell Biol.* **2012**, *22*, 50–60. [[CrossRef](#)] [[PubMed](#)]
14. Bourquin, F.; Capitani, G.; Grütter, M.G. PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism. *Protein Sci.* **2011**, *20*, 1492–1508. [[CrossRef](#)] [[PubMed](#)]
15. Saba, J.D. Fifty years of lyase and a moment of truth: Sphingosine phosphate lyase from discovery to disease. *J. Lipid. Res.* **2019**, *60*, 456–463. [[CrossRef](#)]
16. Lee, M.J.; Thangada, S.; Claffey, K.P.; Ancellin, N.; Liu, C.H.; Kluk, M.; Volpi, M.; Sha’afi, R.I.; Hla, T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. *Cell* **1999**, *99*, 301–312. [[CrossRef](#)]
17. Garcia, J.G.; Liu, F.; Verin, A.D.; Birukova, A.; Dechert, M.A.; Gerthoffer, W.T.; Bamberg, J.R.; English, D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. *J. Clin. Invest.* **2001**, *108*, 689–701. [[CrossRef](#)]
18. Yanagida, K.; Liu, C.H.; Faraco, G.; Galvani, S.; Smith, H.K.; Burg, N.; Anrather, J.; Sanchez, T.; Iadecola, C.; Hla, T. Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 4531–4536. [[CrossRef](#)]
19. van Doorn, R.; Lopes Pinheiro, M.A.; Kooij, G.; Lakeman, K.; van het Hof, B.; van der Pol, S.M.; Geerts, D.; van Horssen, J.; van der Valk, P.; van der Kam, E.; et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. *J. Neuroinflamm.* **2012**, *9*, 133. [[CrossRef](#)]
20. Sanchez, T.; Skoura, A.; Wu, M.T.; Casserly, B.; Harrington, E.O.; Hla, T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. *Arter. Thromb. Vasc. Biol.* **2007**, *27*, 1312–1318. [[CrossRef](#)]

21. Gril, B.; Paranjape, A.N.; Woditschka, S.; Hua, E.; Dolan, E.L.; Hanson, J.; Wu, X.; Kloc, W.; Izycka-Swieszewska, E.; Duchnowska, R.; et al. Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. *Nat. Commun.* **2018**, *9*, 2705. [[CrossRef](#)] [[PubMed](#)]
22. Abbasi, T.; Garcia, J.G. Sphingolipids in lung endothelial biology and regulation of vascular integrity. *Handb. Exp. Pharmacol.* **2013**, 201–226. [[CrossRef](#)]
23. Jho, E.H.; Zhang, T.; Domon, C.; Joo, C.K.; Freund, J.N.; Costantini, F. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol. Cell Biol.* **2002**, *22*, 1172–1183. [[CrossRef](#)] [[PubMed](#)]
24. Tang, C.; Xue, H.L.; Bai, C.L.; Fu, R. Regulation of adhesion molecules expression in TNF-alpha-stimulated brain microvascular endothelial cells by tanshinone IIA: Involvement of NF-kappaB and ROS generation. *Phytother. Res.* **2011**, *25*, 376–380. [[PubMed](#)]
25. Alvarez, S.E.; Harikumar, K.B.; Hait, N.C.; Allegood, J.; Strub, G.M.; Kim, E.Y.; Maceyka, M.; Jiang, H.; Luo, C.; Kordula, T.; et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. *Nature* **2010**, *465*, 1084–1088. [[CrossRef](#)]
26. Christian, F.; Smith, E.L.; Carmody, R.J. The regulation of NF-kappaB subunits by phosphorylation. *Cells* **2016**, *5*, 12. [[CrossRef](#)]
27. Atkins, G.B.; Jain, M.K. Role of Krüppel-like transcription factors in endothelial biology. *Circ. Res.* **2007**, *100*, 1686–1695. [[CrossRef](#)]
28. Cowan, C.E.; Kohler, E.E.; Dugan, T.A.; Mirza, M.K.; Malik, A.B.; Wary, K.K. Krüppel-like factor-4 transcriptionally regulates VE-cadherin expression and endothelial barrier function. *Circ. Res.* **2010**, *107*, 959–966. [[CrossRef](#)]
29. Hait, N.C.; Allegood, J.; Maceyka, M.; Strub, G.M.; Harikumar, K.B.; Singh, S.K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. *Science* **2009**, *325*, 1254–1257. [[CrossRef](#)]
30. Vandembroucke, E.; Mehta, D.; Minshall, R.; Malik, A.B. Regulation of endothelial junctional permeability. *Ann. N. Y. Acad. Sci.* **2008**, *1123*, 134–145. [[CrossRef](#)]
31. Rho, S.S.; Ando, K.; Fukuhara, S. Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions. *J. Nippon. Med. Sch.* **2017**, *84*, 148–159. [[CrossRef](#)] [[PubMed](#)]
32. Mehta, D.; Malik, A.B. Signaling mechanisms regulating endothelial permeability. *Physiol. Rev.* **2006**, *86*, 279–367. [[CrossRef](#)] [[PubMed](#)]
33. Gavard, J. Breaking the VE-cadherin bonds. *FEBS Lett.* **2009**, *583*, 1–6. [[CrossRef](#)] [[PubMed](#)]
34. Sun, J.; Paddock, C.; Shubert, J.; Zhang, H.B.; Amin, K.; Newman, P.J.; Albelda, S.M. Contributions of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) in regulating cell-cell localization. *J. Cell Sci.* **2000**, *113*, 1459–1469.
35. Dudek, S.M.; Jacobson, J.R.; Chiang, E.T.; Birukov, K.G.; Wang, P.; Zhan, X.; Garcia, J.G. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: Roles for cortactin and myosin light chain kinase. *J. Biol. Chem.* **2004**, *279*, 24692–24700. [[CrossRef](#)]
36. Wang, L.; Dudek, S.M. Regulation of vascular permeability by sphingosine 1-phosphate. *Microvasc. Res.* **2009**, *77*, 39–45. [[CrossRef](#)]
37. Adyshev, D.M.; Moldobaeva, N.K.; Elangovan, V.R.; Garcia, J.G.; Dudek, S.M. Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement. *Cell Signal.* **2011**, *23*, 2086–2096. [[CrossRef](#)]
38. Krump-Konvalinkova, V.; Yasuda, S.; Rubic, T.; Makarova, N.; Mages, J.; Erl, W.; Vosseler, C.; Kirkpatrick, C.J.; Tigyi, G.; Siess, W. Stable knock-down of the sphingosine 1-phosphate receptor S1P1 influences multiple functions of human endothelial cells. *Arter. Thromb. Vasc. Biol.* **2005**, *25*, 546–552. [[CrossRef](#)]
39. Mehta, D.; Konstantoulaki, M.; Ahmmed, G.U.; Malik, A.B. Sphingosine 1-phosphate-induced mobilization of intracellular Ca²⁺ mediates rac activation and adherens junction assembly in endothelial cells. *J. Biol. Chem.* **2005**, *280*, 17320–17328. [[CrossRef](#)]
40. Scotti, L.; Di Pietro, M.; Pascuali, N.; Irusta, G.; de Zuniga, I.; Pena, M.G.; Pomilio, C.; Saravia, F.; Tesone, M.; Abramovich, D.; et al. Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome. *Mol. Human Reprod.* **2016**, *22*, 852–866. [[CrossRef](#)]

41. Singleton, P.A.; Dudek, S.M.; Chiang, E.T.; Garcia, J.G. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. *FASEB J.* **2005**, *19*, 1646–1656. [[CrossRef](#)] [[PubMed](#)]
42. Burg, N.; Swendeman, S.; Worgall, S.; Hla, T. Sphingosine 1-phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury. *Arthritis Rheumatol.* **2018**, *70*, 1879–1889. [[CrossRef](#)] [[PubMed](#)]
43. Das, A.; Lenz, S.M.; Awojoodu, A.O.; Botchwey, E.A. Abluminal stimulation of sphingosine 1-phosphate receptors 1 and 3 promotes and stabilizes endothelial sprout formation. *Tissue Eng. Part A* **2015**, *21*, 202–213. [[CrossRef](#)] [[PubMed](#)]
44. Singleton, P.A.; Moreno-Vinasco, L.; Sammani, S.; Wanderling, S.L.; Moss, J.; Garcia, J.G. Attenuation of vascular permeability by methylglucamine: Role of mOP-R and S1P3 transactivation. *Am. J. Respir. Cell Mol. Biol.* **2007**, *37*, 222–231. [[CrossRef](#)]
45. van Wetering, S.; van den Berk, N.; van Buul, J.D.; Mul, F.P.J.; Lommerse, I.; Mous, R.; ten Klooster, J.P.; Zwaginga, J.J.; Hordijk, P.L. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. *Am. J. Physiol.-Cell Physiol.* **2003**, *285*, C343–C352. [[CrossRef](#)]
46. Marcos-Ramiro, B.; Garcia-Weber, D.; Millan, J. TNF-induced endothelial barrier disruption: Beyond actin and Rho. *Thromb. Haemost.* **2014**, *112*, 1088–1102. [[CrossRef](#)]
47. Alsaffar, H.; Martino, N.; Garrett, J.P.; Adam, A.P. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. *Am. J. Physiol.-Cell Physiol.* **2018**, *314*, C589–C602. [[CrossRef](#)]
48. Stamatovic, S.M.; Keep, R.F.; Kunkel, S.L.; Andjelkovic, A.V. Potential role of MCP-1 in endothelial cell tight junction ‘opening’: Signaling via Rho and Rho kinase. *J. Cell Sci.* **2003**, *116*, 4615–4628. [[CrossRef](#)]
49. Roberts, T.K.; Eugenin, E.A.; Lopez, L.; Romero, I.A.; Weksler, B.B.; Couraud, P.O.; Berman, J.W. CCL2 disrupts the adherens junction: Implications for neuroinflammation. *Lab. Investig.* **2012**, *92*, 1213–1233. [[CrossRef](#)]
50. Yang, W.W.; Wang, A.; Zhao, C.; Li, Q.; Pan, Z.; Han, X.; Zhang, C.; Wang, G.; Ji, C.; Wang, G.; et al. miR-125b enhances IL-8 production in early-onset severe preeclampsia by targeting sphingosine-1-phosphate lyase 1. *PLoS ONE* **2016**, *11*, e0166940. [[CrossRef](#)]
51. Chang, E.; Nayak, L.; Jain, M.K. Krüppel-like factors in endothelial cell biology. *Curr. Opin. Hematol.* **2017**, *24*, 224–229. [[CrossRef](#)] [[PubMed](#)]
52. SenBanerjee, S.; Lin, Z.; Atkins, G.B.; Greif, D.M.; Rao, R.M.; Kumar, A.; Feinberg, M.W.; Chen, Z.; Simon, D.I.; Lusinskas, F.W.; et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. *J. Exp. Med.* **2004**, *199*, 1305–1315. [[CrossRef](#)]
53. Hamik, A.; Lin, Z.; Kumar, A.; Balcells, M.; Sinha, S.; Katz, J.; Feinberg, M.W.; Gerzsten, R.E.; Edelman, E.R.; Jain, M.K. Krüppel-like factor 4 regulates endothelial inflammation. *J. Biol. Chem.* **2007**, *282*, 13769–13779. [[CrossRef](#)]
54. Fahmy, R.G.; Waldman, A.; Zhang, G.; Mitchell, A.; Tedla, N.; Cai, H.; Geczy, C.R.; Chesterman, C.N.; Perry, M.; Khachigian, L.M. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. *Nat. Biotechnol.* **2006**, *24*, 856–863. [[CrossRef](#)]
55. Ahmad, M.; Theofanidis, P.; Medford, R.M. Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha. *J. Biol. Chem.* **1998**, *273*, 4616–4621. [[CrossRef](#)] [[PubMed](#)]
56. Pietersma, A.; Tilly, B.C.; Gaestel, M.; de Jong, N.; Lee, J.C.; Koster, J.F.; Sluiter, W. P38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. *Biochem. Biophys. Res. Commun.* **1997**, *230*, 44–48. [[CrossRef](#)]
57. Goebeler, M.; Kilian, K.; Gillitzer, R.; Kunz, M.; Yoshimura, T.; Bröcker, E.B.; Rapp, U.R.; Ludwig, S. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. *Blood* **1999**, *93*, 857–865. [[CrossRef](#)] [[PubMed](#)]
58. Rajan, S.; Ye, J.; Bai, S.; Huang, F.; Guo, Y.L. NF-kappa B, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells. *J. Cell. Biochem.* **2008**, *105*, 477–486. [[CrossRef](#)] [[PubMed](#)]

59. Li, X.; Stankovic, M.; Bonder, C.S.; Hahn, C.N.; Parsons, M.; Pitson, S.M.; Xia, P.; Proia, R.L.; Vadas, M.A.; Gamble, J.R. Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. *Blood* **2008**, *111*, 3489–3497. [[CrossRef](#)] [[PubMed](#)]
60. Zhao, Y.; Gorshkova, I.A.; Berdyshev, E.; He, D.; Fu, P.; Ma, W.; Su, Y.; Usatyuk, P.V.; Pendyala, S.; Oskouian, B.; et al. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. *Am. J. Respir. Cell. Mol. Biol.* **2011**, *45*, 426–435. [[CrossRef](#)]
61. Feuerborn, R.; Besser, M.; Poti, F.; Burkhardt, R.; Weissen-Plenz, G.; Ceglarek, U.; Simoni, M.; Proia, R.L.; Freise, H.; Nofer, J.R. Elevating endogenous sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein receptor-deficient (LDL-R (-/-)) mice. *Thromb. Haemost.* **2018**, *118*, 1470–1480. [[CrossRef](#)] [[PubMed](#)]
62. Thomas, G.W.; Rael, L.T.; Bar-Or, R.; Mains, C.W.; Slone, D.S.; Boyd, S.R.; Bar-Or, D. Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics. *Biochem. Biophys. Res. Commun.* **2012**, *421*, 707–712. [[CrossRef](#)]
63. Surapisitchat, J.; Jeon, K.I.; Yan, C.; Beavo, J.A. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. *Circ. Res.* **2007**, *101*, 811–818. [[CrossRef](#)]
64. Surapisitchat, J.; Beavo, J.A. Regulation of endothelial barrier function by cyclic nucleotides: The role of phosphodiesterases. *Handb. Exp. Pharmacol.* **2011**, 193–210. [[CrossRef](#)]
65. Zheng, X.; Zhang, W.; Hu, X. Different concentrations of lipopolysaccharide regulate barrier function through the PI3K/Akt signalling pathway in human pulmonary microvascular endothelial cells. *Sci. Rep.* **2018**, *8*, 9963. [[CrossRef](#)] [[PubMed](#)]
66. Bazzoni, G.; Dejana, E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. *Physiol. Rev.* **2004**, *84*, 869–901. [[CrossRef](#)] [[PubMed](#)]
67. Karczewski, J.; Groot, J. Molecular physiology and pathophysiology of tight junctions III. Tight junction regulation by intracellular messengers: Differences in response within and between epithelia. *Am. J. Physiol. Gastrointest Liver Physiol.* **2000**, *279*, G660–G665. [[CrossRef](#)]
68. Barabutis, N.; Verin, A.; Catravas, J.D. Regulation of pulmonary endothelial barrier function by kinases. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2016**, *311*, L832–L845. [[CrossRef](#)]
69. Stuart, R.O.; Sun, A.; Panichas, M.; Hebert, S.C.; Brenner, B.M.; Nigam, S.K. Critical role for intracellular calcium in tight junction biogenesis. *J. Cell Physiol.* **1994**, *159*, 423–433. [[CrossRef](#)]
70. Sandoval, R.; Malik, A.B.; Minshall, R.D.; Kouklis, P.; Ellis, C.A.; Tiruppathi, C. Ca(2+) signalling and PKC α activate increased endothelial permeability by disassembly of VE-cadherin junctions. *J. Physiol.* **2001**, *533*, 433–445. [[CrossRef](#)]
71. Ihlefeld, K.; Claas, R.F.; Koch, A.; Pfeilschifter, J.M.; Meyer zu Heringdorf, D. Evidence for a link between histone deacetylation and Ca(2)+ homeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts. *Biochem. J.* **2012**, *447*, 457–464. [[CrossRef](#)] [[PubMed](#)]
72. Claas, R.F.; ter Braak, M.; Hegen, B.; Hardel, V.; Angioni, C.; Schmidt, H.; Jakobs, K.H.; Van Veldhoven, P.P.; Meyer zu Heringdorf, D. Enhanced Ca²⁺ storage in sphingosine-1-phosphate lyase-deficient fibroblasts. *Cell Signal.* **2010**, *22*, 476–483. [[CrossRef](#)] [[PubMed](#)]
73. Itagaki, K.; Yun, J.K.; Hengst, J.A.; Yatani, A.; Hauser, C.J.; Spolarics, Z.; Deitch, E.A. Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca²⁺ metabolism. *J. Pharmacol. Exp. Ther.* **2007**, *323*, 186–191. [[CrossRef](#)]
74. Nagpala, P.G.; Malik, A.B.; Vuong, P.T.; Lum, H. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. *J. Cell Physiol.* **1996**, *166*, 249–255. [[CrossRef](#)]
75. Shao, B.; Bayraktutan, U. Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-beta. *Diabetes Obes. Metab.* **2013**, *15*, 993–999. [[CrossRef](#)]
76. Rigor, R.R.; Beard, R.S., Jr.; Litovka, O.P.; Yuan, S.Y. Interleukin-1 β -induced barrier dysfunction is signaled through PKC- θ in human brain microvascular endothelium. *Am. J. Physiol. Cell Physiol.* **2012**, *302*, C1513–C1522. [[CrossRef](#)]
77. Minshall, R.D.; Vandenbroucke, E.E.; Holinstat, M.; Place, A.T.; Tiruppathi, C.; Vogel, S.M.; van Nieuw Amerongen, G.P.; Mehta, D.; Malik, A.B. Role of protein kinase C ζ in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers. *Microvasc. Res.* **2010**, *80*, 240–249. [[CrossRef](#)]

78. Sonobe, Y.; Takeuchi, H.; Kataoka, K.; Li, H.; Jin, S.; Mimuro, M.; Hashizume, Y.; Sano, Y.; Kanda, T.; Mizuno, T.; et al. Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner. *J. Biol. Chem.* **2009**, *284*, 31834–31842. [[CrossRef](#)]
79. Harrington, E.O.; Brunelle, J.L.; Shannon, C.J.; Kim, E.S.; Mennella, K.; Rounds, S. Role of protein kinase C isoforms in rat epididymal microvascular endothelial barrier function. *Am. J. Respir. Cell Mol. Biol.* **2003**, *28*, 626–636. [[CrossRef](#)]
80. Bektas, M.; Allende, M.L.; Lee, B.G.; Chen, W.; Amar, M.J.; Remaley, A.T.; Saba, J.D.; Proia, R.L. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. *J. Biol. Chem.* **2010**, *285*, 10880–10889. [[CrossRef](#)]
81. Gerl, M.J.; Bittl, V.; Kirchner, S.; Sachsenheimer, T.; Brunner, H.L.; Luchtenborg, C.; Özbacı, C.; Wiedemann, H.; Wegehingel, S.; Nickel, W.; et al. Sphingosine-1-phosphate lyase deficient cells as a tool to study protein lipid interactions. *PLoS ONE* **2016**, *11*, e0153009. [[CrossRef](#)] [[PubMed](#)]
82. Dennhardt, S.; Finke, K.R.; Huwiler, A.; Coldewey, S.M. Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms. *Biochim. Biophys. Acta-Mol. Basis Dis.* **2019**, *1865*, 774–781. [[CrossRef](#)] [[PubMed](#)]
83. Anjum, F.; Joshi, K.; Grinkina, N.; Gowda, S.; Cutaia, M.; Wadgaonkar, R. Role of sphingomyelin synthesis in pulmonary endothelial cell cytoskeletal activation and endotoxin-induced lung injury. *Am. J. Respir. Cell Mol. Biol.* **2012**, *47*, 94–103. [[CrossRef](#)] [[PubMed](#)]
84. Lindner, K.; Uhlig, U.; Uhlig, S. Ceramide alters endothelial cell permeability by a nonapoptotic mechanism. *Br. J. Pharmacol.* **2005**, *145*, 132–140. [[CrossRef](#)] [[PubMed](#)]
85. Kady, N.M.; Liu, X.W.; Lydic, T.A.; Syed, M.H.; Navitskaya, S.; Wang, Q.; Hammer, S.S.; O'Reilly, S.; Huang, C.; Seregin, S.S.; et al. ELOVL4-mediated production of very long-chain ceramides stabilizes tight junctions and prevents diabetes-induced retinal vascular permeability. *Diabetes* **2018**, *67*, 769–781. [[CrossRef](#)]
86. Magaye, R.R.; Savira, F.; Hua, Y.; Kelly, D.J.; Reid, C.; Flynn, B.; Liew, D.; Wang, B.H. The role of dihydrosphingolipids in disease. *Cell Mol. Life Sci.* **2019**, *76*, 1107–1134. [[CrossRef](#)]
87. Li, G.L.; Simon, M.J.; Cancel, L.M.; Shi, Z.D.; Ji, X.; Tarbell, J.M.; Morrison, B., 3rd; Fu, B.M. Permeability of endothelial and astrocyte cocultures: In vitro blood-brain barrier models for drug delivery studies. *Ann. Biomed. Eng.* **2010**, *38*, 2499–2511. [[CrossRef](#)]
88. Schmidt, H.; Schmidt, R.; Geisslinger, G. LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. *Prostaglandins Other Lipid. Mediat.* **2006**, *81*, 162–170. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).